NTRK1 and neoplasm: Specifically, MET amplification, BRAFV600E mutation or hotspot mutations involving KRAS have been shown to emerge in tumour and/or plasma samples from patients with TRK fusion-positive cancers that have progressed on a TRK inhibitor [27].